Article Text

SAT0464 Disease Status Influences the Balance and Cytokine Profile in Patients with Juvenile Idiopathic Arthritis
  1. G. Almanzar1,
  2. K. Sustal1,
  3. R. Trippen1,
  4. K. Höfner1,
  5. M. Prelog1
  1. 1Department of Pediatrics, University of Würzburg, Würzburg, Germany


Background Juvenile idiopathic arthritis (JIA) is an inflammatory disorder with heterogeneous clinical presentation. IL-17-producing T-cells (Th17) have been identified as pro-inflammatory cells in several autoimmune conditions.

Objectives This study evaluated the phenotype and the cytokine-production profile of T-cells in JIA patients with active disease (group 1, n=17), remission on medication (group 2, n=39), remission off medication (group 3, n=10), disease flare after remission (group 4, n=16) and healthy donors (HD, n=28).

Methods The phenotype characterization and the intracellular production of IFNgamma, TNFalpha, and IL-17 on naive (CD28+CD45RO-), memory (CD28+CD45RO+), effector (CD28-CD45RO+), terminally differentiated T-cells (CD28-CD45RO-) and regulatory T-cells (Tregs, CD25+CD127-FoxP3+) CD4+ T-cells were investigated by flowcytometry.

Results IFNgamma-producing CD4+ T-cells (4.9% versus 6.9%) and Tregs (2.9% versus 3.8%) were significantly lower in JIA than HD. Moreover, memory CD4+ T-cells produced lower amounts of IFNgamma in JIA group 4 (6.3%), group 1 (6.3%) and group 2 (7.6%) compared to HD (11.3%). Interestingly, the memory CD4+ T-cell population also showed lower TNFalpha production in the same groups (group 4:20.3%; group 1:18.5%; group 2:20.0%; HD:29.9%). No differences were observed in the IL-17 production by CD4+ T-cells between JIA and HD. However, patients with disease flare showed higher proportions of IL-17-producing CD4+CD45RO-CD28-CD27- T-cells (1.3%) than patients in remission off medication (0.6%)

Conclusions Our findingssuggest, depending on disease activity, an imbalance in the cytokine production profile in memory and effector T-cell subpopulations in JIA patients. This may be increasingly relevant for novel therapeutic approaches with early treatment of active disease with biologic drugs.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.